2017 Executive Sponsor

PwC UK

2017 Associate Sponsors

Be The Partner
Cmed
Langland

2017 Exhibitors

Medicodose

2017 Supporting Partners

CISCRP
MedCity

2017 Media Partners

BioPharm Insight
CanBiotech
Labiotech_eu
MNT
Pharmalicensing
Pharmaphorum
Technology Networks

Event Blog


  • November 18, 2016

  • EMA Begins Providing Public Access to Clinical Reports

    Beginning in October 2016, the European Medicines Agency (EMA) has made a decision to support transparency in clinical trials by giving open access to clinical reports for new medicines for human use authorized in the European Union (EU). EMA is the first regulatory authority worldwide to provide such broad access to clinical data. “Transparency on clinical data is a […]

    Beginning in October 2016, the European Medicines Agency (EMA) has made a decision to support transparency in clinical trials by giving open access to clinical reports for new medicines for human use authorized in the European Union (EU). EMA is the first regulatory authority worldwide to provide such broad access to clinical data.

    logo_emea
    “Transparency on clinical data is a longstanding commitment from EMA and today, we are delivering on our promise to give access to the data on which our recommendations are based”, explained EMA’s Executive Director Guido Rasi. “Our initiative has shaped the global debate towards more transparency. It will benefit academic research and the practice of medicine as a whole.”

    With the EMA’s new, proactive approach to providing access to the data, increased transparency will allow for:

    – Patients and healthcare professionals to find out more information about the data concerning the approval of medicines they are taking or prescribing

    – Independent re-analysis of data by academics and researchers after a medicine has been approved, thus increasing scientific knowledge, and potentially further informing regulatory decision making in the future

    – Innovation, as the shared knowledge about a medicine helps developers learn from the experience of others and can lead to more efficient medicine development programs.

    To read the full article, click here.

    For more information on DPharm EU, click here.

    Read More

  • July 6, 2016

  • Dpharm Europe Speaker Alexander Masters on Crowd Funding Cancer Cures

    We are delighted to highlight the latest piece printed in the London Telegraph by DPharm Europe speaker, Alexander Masters on the latest in a new financial paradigm to help fight cancer. From the Telegraph: The first person in the world to receive the only crowd-funded cancer drug in history will be Jan Smørlung, a village […]

    Alexander Masters, Author, Campaigner and Co-Founder, iCancer.org.uk

    Alexander Masters & Craig Lipset at DPharm Europe

    We are delighted to highlight the latest piece printed in the London Telegraph by DPharm Europe speaker, Alexander Masters on the latest in a new financial paradigm to help fight cancer.

    From the Telegraph:

    The first person in the world to receive the only crowd-funded cancer drug in history will be Jan Smørlung, a village fire inspector, who doesn’t mind us pointing our camera lens at his groin. ‘Yes, thank you. I am happy to assist the world,’ he says.

    A plump, healthy-looking man with a fresh haircut, wearing a white T-shirt, he looks like someone who rows out into misty forest lakes to catch a fish for breakfast. He has two children, six grandchildren and not much time.

    For over a decade, Jan’s consultant, world famous clinician Kjell Öberg, has held back the inevitable with every treatment so far known to medicine, from chemotherapy to small radioactive balls dribbled into Jan’s blood.

    Continue Reading Here.

    Listen to Alexander’s Story on PharmaTalk Radio

    Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer speaks with Alexander Masters, Author, Medical Campaigner and Co-Founder, iCancer.org.uk on:

    • The story of the formation of iCancer.org.uk and the Oncolytic Virus Fund
    • An alternative way to make clinical trials more accessible
    • Ethical and moral issues
    • A possible disruptive and sustainable model for other neglected medicines

    Listen to the program here.

    Read More

  • April 4, 2016

  • PharmaTalkRadio Covers A New Economic Solution to Drive Cures to Patients

    PharmaTalkRadio features a radio discussion on a new model to repurpose drugs in unsolved diseases. Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve […]

    PharmaTalkRadio features a radio discussion on a new model to repurpose drugs in unsolved diseases.

    Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve the necessary ROI.

     Bruce Bloom, Cures Within Reach presenting at Dpharm Europe 2016

    Bruce Bloom, Cures Within Reach presenting at Dpharm Europe 2016

    Cures Within Reach, FindaCure, Numbers For Good and the National Health Service in England are working together to the create a new economic solution to this problem by piloting the first ever Rare Disease Generic Drug Repurposing Social Impact Bond (SIB).

    This SIB would be a “pay for success” initiative, in which investors fund the proof of concept repurposing clinical trials and the government provides a payment to the SIB for any repurposed therapies that both improve patient outcomes and reduce healthcare costs. The government success payment would allow the SIB to repay the investors, and have additional funds for the next group of repurposing clinical trials, creating a sustainable funding source for generic drug repurposing.

    Producer:
    Valerie Bowling
, Executive Director, Conference Forum

    Guest Host:
    Bruce Bloom, JD, 
President & CSO, Cures Within Reach

    Panelists:
    James Potter, 
Investment Director, Numbers for Good
    Flóra Raffai
, Executive Director, Findacure
    Dr Rick Thompson
, Scientific Officer, Findacure

    Listen to the show here: http://www.blogtalkradio.com/pharmatalk/2016/04/01/a-new-economic-solution-to-drive-cures-to-patients

     

    Bruce Bloom led panels at both the Dpharm, Disruptive Innovations to Advance Clinical Trials conferences in Europe as well as in the US. Our next DPharm event will take place September 20-21 in Boston. For more information about other radio programs and the next DPharm event, please visit www.theconferenceforum.org.

    Helpful Websites:
    findacure.org.uk
    numbersforgood.com

    Read More

  • January 19, 2016

  • Singing Opera with Someone Else’s Lungs

    In September 2015, we were honored to open the 5th annual DPharm conference with Charity Sunshine Tillemann-Dick, a coloratura soprano and composer. After being diagnosed with Idiopathic Pulmonary Hypertension she received two double lung transplants. We share her story, a journey you will never forget and it reminds all of us the central reason why […]

    In September 2015, we were honored to open the 5th annual DPharm conference with Charity Sunshine Tillemann-Dick, a coloratura soprano and composer. After being diagnosed with Idiopathic Pulmonary Hypertension she received two double lung transplants. We share her story, a journey you will never forget and it reminds all of us the central reason why we must never stop innovating to advance drug development.

     

    The next Dpharm US conference is scheduled for September 20-21, 2016 in Boston. The DPharm Europe conference is scheduled for February 9-10, 2016 in London.

     

    Read More

  • November 11, 2015

  • DPharm Europe Venue Announced

    In the spirit of biomedical research investments to make the St Pancras / Kings Cross area of London the center for R&D innovation, we are pleased to announce that DPharm Europe will be held at the St Pancras Renaissance Hotel in London, UK. On one side of the hotel, the brand new Francis Crick Institute […]

    In the spirit of biomedical research investments to make the St Pancras / Kings Cross area of London the center for R&D innovation, we are pleased to announce that DPharm Europe will be held at the St Pancras Renaissance Hotel in London, UK.

    stp

    The St Pancras Hotel

    On one side of the hotel, the brand new Francis Crick Institute is due to open in early 2016 and will house about 1,250 scientists from various disciplines across the globe. Down the street is the Wellcome Trust and Collection which explores the connections between medicine, life and art in the past, present and future. Other associated developments in the area include a teaching laboratory to school students, involvement of public in science programs, a 450-seat auditorium and exhibition space, improvements to community spaces, voluntary educational programs, a pedestrian and cycle access way and aid for local businesses.

    3158917_db1d70ee

    St Pancras Station

    Connected to the hotel is the St Pancras Station which opened in 1868. It is considered a masterpieceof victorian gothic architecture. The station is at the heart of central London with more underground connections than any other London station. It is also home to the Eurostar for direct and easy routes to Paris and Brussels and filled with shops and restaurants. Both the station and the hotel have been beautifully restored with a series of wrought iron ribs resulting in soaring ceilings. For all you Harry Potter fans, you can visit Platform 9 3/4 across from St Pancras at the Kings Cross Station about a five-minute walk.

    DPharm Europe will be held in the Hansom Hall room in the St Pancras Renaissance hotel. The room was especially selected for DPharm Europe for its inspiring and unique space providing an excellent environment for an event dedicated to innovation in drug development.

    For more information about DPharm Europe or if you are interested in attending, speaking or sponsoring, please contact Jennifer Moran at Jennifer@tcfllc.org.

    Read More

  • April 30, 2015

  • DPharm Makes Stuff Happen!

    We are so pleased to see another exciting outcome from the DPharm conference. Congratulations to TrialReach on making news in Forbes from their work with industry in registering patients in trials faster. Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster Two years ago, Pfizer, Novartis, and Eli Lilly set aside […]

    330_24529_full-800w

    Jeff Kasher, formerly vice president of Clinical Innovation and Implementation at Eli Lilly and president of Patients Can’t Wait with Pablo Gravier, CEO, TrialReach at the inaugural DPharm Europe

    We are so pleased to see another exciting outcome from the DPharm conference. Congratulations to TrialReach on making news in Forbes from their work with industry in registering patients in trials faster.

    Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster

    Two years ago, Pfizer, Novartis, and Eli Lilly set aside competition to form a consortium called Patients to Trials. Goal: To solve an issue that has bedeviled their industry and slowed drug development—namely how to enroll patients in clinical trials faster. According to CenterWatch, 75% of the public is unaware of clinical studies, and nearly half of trials don’t fulfill their recruitment goals, causing delays. “If we can compress the time it takes to enroll a trial, we can get medicines to patients much faster,” says Jeff Kasher, formerly vice president of Clinical Innovation and Implementation at Eli Lilly, and president of Patients Can’t Wait.

    Continue Reading here: http://www.forbes.com/sites/zinamoukheiber/2015/04/23/drug-companies-pin-hopes-on-trialreach-to-enroll-patients-in-clinical-trials-faster/

    Read More

  • February 10, 2015

  • Conference Forum at 10 Downing Street for Transatlantic Innovation Meeting

    London, England: The Conference Forum helped organize the first ever meeting at 10 Downing Street dedicated to transatlantic innovation in drug development, patient access and the role of patients and big data. Healthcare policy specialists from Her Majesty’s government joined with a number of senior executives from across the pharmaceutical industry to discuss the central theme of how we can work together to accelerate drug […]

    London, England: The Conference Forum helped organize the first ever meeting at 10 Downing Street dedicated to transatlantic innovation in drug development, patient access and the role of patients and big data. Healthcare policy specialists from Her Majesty’s government joined with a number of senior executives from across the pharmaceutical industry to discuss the central theme of how we can work together to accelerate drug development across boarders and how we can better apply innovation. Other topics included:

    • New models of care
    • The concept of smart reimbursement
    • Efficiency research vs effective research
    • Real world research settings
    • Making research more relevant to patients
    • Access to innovation
    Sara Kerruish and Valerie Bowling with the 10 Downing Street Life Science Meeting Participants

    Sara Kerruish and Valerie Bowling with the 10 Downing Street Life Science Meeting Participants

    After the meeting, several members of the group attended a tea reception at the Ritz, kindly sponsored by Trial Reach, whom we would like to thank for all their support. The timing of the meeting worked beautifully as it fell the day before the launch of DPharm Europe, designed to find better and more innovative ways of doing clinical trials. If you’ve not been able to make the DPharm Europe event, stay tuned for the 5th annual DPharm US event in Boston, September 9-11, 2015.

    For more information, visit, www.theconferenceforum.org

    Read More

  • December 17, 2014

  • Will Patients be Able to Pay to Get into a Clinical Trial?

    Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised – by one wealthy individual primarily, in return for being […]

    Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised – by one wealthy individual primarily, in return for being in the trial. Could this be a new paradigm to fund research gaps especially for rare diseases? What moral and ethical issues does this bring up?

    We’re so pleased to announce that the scientist behind the virus, Professor Magnus Essand together with Alexander Masters will share their remarkable journey at the DPharm Europe event taking place in London on February 11th. For more information on the story see icancer.org.uk and
    http://www.telegraph.co.uk/health/11189163/How-the-wealthy-paying-to-be-guinea-pigs-ini-clinical-trials-could-help-cure-us-all.html

    For more information about Dpharm Europe, visit http://theconferenceforum.org/conferences/disruptive-innovations-europe/overview/

    Read More

  • December 3, 2014

  • Building a European Adaptive Trial Delivery Machine for Dementia @ Dpharm Europe

    We are so pleased to welcome Professor Craig Ritchie, Professor of the Psychiatry of Ageing, Centre for Clinical Brain Sciences University of Edinburgh and Visiting Professor Imperial College London to the DPharm Europe conference. DPharm Europe features global examples of disruptive innovation in clinical trials. Not all innovation is disruptive, but in the case of […]

    icimages

    Professor Craig Ritchie

    We are so pleased to welcome Professor Craig Ritchie, Professor of the Psychiatry of Ageing, Centre for Clinical Brain Sciences University of Edinburgh and Visiting Professor Imperial College London to the DPharm Europe conference.

    DPharm Europe features global examples of disruptive innovation in clinical trials. Not all innovation is disruptive, but in the case of Dr Ritchie’s work, a first of its kind, we believe it is a unique example of innovation.

    The professor will share his journey on how he challenged a traditional system to propose substantial changes to develop a public-private collaborative European clinical platform for preventing dementia: The EPAD (European Prevention of Alzheimer’s Dementia). More specifically Dr Ritchie addresses:

    • – The questions to ask in challenging old ways of doing things
    • – Forming and communicating a vision
    • – What it takes to build public, private and patient collaboration
    • – Execution and next steps

    Dpharm Europe takes place in London on February 10-11, 2015.

    Read More